Hearn, B., et al.,
Low Adherence of HIV Providers to Practice Guidelines for Hepatocellular Carcinoma Screening in HIV/Hepatitis B Co-infection.
Clin Infect Dis, 2015.
A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene.
J Hepatol, 2015.
Martel-Laferriere, V., et al.,
Clinical characteristics of human immunodeficiency virus patients being referred for liver transplant evaluation: a descriptive cohort study.
Transpl Infect Dis, 2015.
Bichoupan, K., et al.,
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
Hepatology, 2014. 60(4): p. 1187-95.
Sefcik, R.K., et al.,
elaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4.
J Infect Dis, 2014. 210(11): p. 1855-6.
Ge, X., et al.,
High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD).
J Biol Chem, 2014. 289(33): p. 22672-91.
Bichoupan, K., et al.,
Commentary: real-world triple therapy experience treating hepatitis C virus – authors’ reply.
Aliment Pharmacol Ther, 2014. 39(5): p. 543.
Branch, A.D., et al.,
Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study.
Liver Transpl, 2014. 20(2): p. 156-64.
Bichoupan, K., et al.,
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
Aliment Pharmacol Ther, 2014. 39(2): p. 209-16.
Crismale, J.F., et al.,
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Liver Int, 2014. 34(7): p. 1018-24.
Branch, A.D., et al.,
Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder.
Clin Infect Dis, 2013. 57(11): p. 1618-25.
Martel-Laferriere, V., et al.,
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
HIV Med, 2014. 15(2): p. 108-15.
Branch, A.D., et al.,
In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.
Am J Clin Nutr, 2013. 98(2): p. 423-9.
Rahman, A.H. and A.D. Branch,
Vitamin D for your patients with chronic hepatitis C?
J Hepatol, 2013. 58(1): p. 184-9.
Fierer, D.S., et al.,
Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men.
Clin Infect Dis, 2012. 55(6): p. 887-8; author reply 888-9.
Branch, A.D., et al.,
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy.
Clin Infect Dis, 2012. 55(1): p. 137-44.
Gutierrez, J.A., N. Parikh, and A.D. Branch,
Classical and emerging roles of vitamin D in hepatitis C virus infection.
Semin Liver Dis, 2011. 31(4): p. 387-98.
Ahmad, J., F.J. Eng, and A.D. Branch,
HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene.
Semin Liver Dis, 2011. 31(4): p. 347-55.
Gutierrez, J.A., et al.,
Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid.
J Virol Methods, 2011. 171(1): p. 169-75.
Branch, A.D. and C.M. Rice,
Antisense gets a grip on miR-122 in chimpanzees.
Sci Transl Med, 2010. 2(13): p. 13ps1.
Fishman, S.L., et al.,
Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.
Clin Cancer Res, 2009. 15(9): p. 3205-13.
Eng, F.J., et al.,
Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms.
J Virol, 2009. 83(7): p. 3104-14.
Schiano, T.D., et al.,
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors.
Hepatology, 2005. 42(6): p. 1420-8.